Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
Alexander E. Perl
No relevant relationships to disclose
Hartmut Dohner
Consultant or Advisory Role - Ambit BioSciences
Philippe H. Rousselot
No relevant relationships to disclose
Jean-Pierre Marie
Other Remuneration - Ambit BioSciences
Giovanni Martinelli
No relevant relationships to disclose
Neil P. Shah
No relevant relationships to disclose
Mark J. Levis
Consultant or Advisory Role - Astellas Pharma
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Jorge E. Cortes
Consultant or Advisory Role - Novartis